세계의 HIV 진단 시장 예측(-2030년) : 검사 유형별, 제품별, 최종사용자별, 지역별
HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030
상품코드:1671377
리서치사:MarketsandMarkets
발행일:2025년 02월
페이지 정보:영문 274 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 HIV 진단 시장 규모는 2025년 32억 5,000만 달러에서 2030년에는 53억 1,000만 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR은 10.3%에 달할 것으로 보이고 있습니다.
조사 범위
조사 대상연도
2022-2030년
기준연도
2024년
예측 기간
2025-2030년
검토 단위
금액(달러)
부문
검사 유형별, 제품별, 최종사용자별, 지역별
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가
HIV 진단 시장은 HIV/AIDS 유병률 증가, 수혈 및 헌혈 증가, POC 진단 키트 및 기기가 제공하는 이점, HIV 인식 개선에 대한 관심 증가 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 그러나 높은 핵산 검사 비용, 운영상의 장벽, 숙련된 검사 기술자 부족 등은 시장 성장을 어느 정도 억제할 것으로 예상됩니다.
조기 HIV 검사를 장려하는 정부 주도의 보건 활동과 광범위한 인식 개선 캠페인은 시장 성장의 주요 촉진요인입니다. 또한 신속한 검사 기술의 지속적인 발전과 자가 테스트 키트의 가용성 및 가격 상승은 환자들의 순응도를 향상시키고 채택률을 높이는 데 기여하고 있습니다. 진단 실험실의 확대, 진단에 인공지능의 통합, 의료 기관과 민간 기업 간의 협력 관계의 확대는 시장 확대에 기여하고 있습니다.
그러나 고가의 진단 검사 비용, 원격지에서의 제한된 의료 서비스 접근성, 검사를 시행하고 해석할 수 있는 숙련된 전문가 부족 등 성장에 걸림돌이 될 수 있는 문제도 있습니다. 규제 장벽과 일부 검사법의 정확성 및 신뢰성에 대한 우려도 잠재적인 장벽으로 작용하고 있습니다.
이러한 어려움에도 불구하고 HIV 진단 시장은 인지도 향상, 의료 인프라 개선, HIV 검진 프로그램에 대한 정부 예산 증가, 신속하고 간편하며 정확한 검사 솔루션에 대한 수요 증가 등을 바탕으로 견고한 성장이 예상됩니다. 조기 발견과 적시 개입에 대한 관심이 높아지는 가운데, 현장 검사 분야의 기술 혁신과 함께 향후 수년간 시장 진출기업에게 큰 기회를 제공할 것으로 보입니다.
세계의 HIV 진단 시장에 대해 조사했으며, 검사 유형별, 제품별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 개요
제4장 주요 인사이트
제5장 시장 개요
서론
시장 역학
고객 비즈니스에 영향을 미치는 동향/혼란
가격 분석
밸류체인 분석
공급망 분석
에코시스템 분석
기술 분석
투자와 자금조달 시나리오
특허 분석
무역 분석
2025-2026년의 주요 컨퍼런스와 이벤트
사례 연구 분석
규제 상황
Porter's Five Forces 분석
주요 이해관계자와 구입 기준
AI/생성형 AI가 HIV 진단 시장에 미치는 영향
제6장 HIV 진단 시장(검사 유형별)
서론
스크리닝 검사
확정 검사
모니터링 검사
기타
제7장 HIV 진단 시장(제품별)
서론
기기
소프트웨어와 서비스
제8장 HIV 진단 시장(최종사용자별)
서론
진단 검사실
병원
혈액은행
홈케어
기타
제9장 HIV 진단 시장(지역별)
서론
북미
북미의 거시경제 전망
미국
캐나다
유럽
유럽의 거시경제 전망
독일
영국
프랑스
이탈리아
스페인
기타
아시아태평양
아시아태평양의 거시경제 전망
중국
일본
인도
기타
라틴아메리카
라틴아메리카의 거시경제 전망
브라질
멕시코
기타
중동 및 아프리카
HIV 진단과 외과수술의 증가가 시장을 활성화
중동 및 아프리카의 거시경제 전망
GCC 국가
HIV 검사에 대한 주목의 증가와 헬스케어 인프라의 개선이 시장의 성장을 지원한다.
GCC 국가의 거시경제 전망
제10장 경쟁 구도
개요
주요 참여 기업의 전략/강점
매출 분석, 2021-2023년
시장 점유율 분석, 2023년
기업 평가 매트릭스 : 주요 참여 기업, 2023년
기업 평가 매트릭스 : 스타트업/중소기업, 2023년
기업 평가와 재무 지표
브랜드/제품 비교
경쟁 시나리오
제11장 기업 개요
주요 참여 기업
ABBOTT
SIEMENS HEALTHINEERS
GRIFOLS, S.A.
DANAHER CORPORATION
THERMO FISHER SCIENTIFIC INC.
BIO-RAD LABORATORIES, INC.
F. HOFFMANN-LA ROCHE LTD.
기타 기업
BIOMERIEUX
HOLOGIC, INC.
QIAGEN
BD
TRINITY BIOTECH
ORASURE TECHNOLOGIES, INC.
BIOSYNEX SA
WONDFO
GETEIN BIOTECH, INC.
MERIL LIFE SCIENCES PVT. LTD.
ACCUBIOTECH CO., LTD.
BIOLYTICAL LABORATORIES INC.
BIO LAB DIAGNOSTICS(I) PRIVATE LIMITED
ALPINE BIOMEDICALS PVT LTD.
MOLBIO DIAGNOSTICS PVT. LTD.
FORTRESS DIAGNOSTICS
ADVACARE PHARMA(ACCUQUIK)
ADALTIS S.R.L.
제12장 부록
KSA
영문 목차
영문목차
The global HIV diagnostics market is projected to reach USD 5.31 Billion by 2030 from USD 3.25 Billion in 2025, at a CAGR of 10.3% during the forecast period.
Scope of the Report
Years Considered for the Study
2022-2030
Base Year
2024
Forecast Period
2025-2030
Units Considered
Value (USD)
Segments
product, test type, end user, and region
Regions covered
North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries
The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent.
Government-led health initiatives and widespread public awareness campaigns encouraging early HIV testing are key drivers of market growth. Additionally, continuous advancements in rapid testing technologies, along with the increasing availability and affordability of self-testing kits, are improving patient compliance and boosting adoption rates. The expansion of diagnostic laboratories, integration of artificial intelligence in diagnostics, and growing collaborations between healthcare organizations and private entities further contribute to market expansion.
However, certain challenges may hinder growth, including the high cost of diagnostic tests, limited access to healthcare in remote regions, and a shortage of skilled professionals to conduct and interpret tests. Regulatory hurdles and concerns regarding the accuracy and reliability of some testing methods also pose potential barriers.
Despite these challenges, the HIV diagnostics market is expected to experience steady growth, driven by increasing awareness, improved healthcare infrastructure, rising government funding for HIV screening programs, and the growing demand for fast, convenient, and highly accurate testing solutions. The increasing focus on early detection and timely intervention, combined with technological innovations in point-of-care testing, is likely to create significant opportunities for market players in the coming years. "The consumables segment accounted for the largest share of the market in 2024, by product."
The HIV diagnostics market is classified by product type into consumables, instruments, and software & services. In 2024, the consumables segment dominated the market, driven by the recurring demand from laboratories and hospitals, the rising prevalence of HIV/AIDS, and government initiatives supporting the development of advanced consumables.
"The confirmatory tests segment accounted for the largest share of the market in 2024, by test type."
By test type, the market is segmented into screening tests, confirmatory tests, and monitoring tests. The monitoring tests segment held the largest share in 2024 and is expected to grow at the highest CAGR. This growth is fueled by increasing awareness of HIV testing, a high volume of monitoring test samples, and the expansion of diagnostic laboratories specializing in HIV/AIDS testing. Additionally, advancements in monitoring test kits are further accelerating the segment's expansion.
"Diagnostic Laboratories segment dominated the HIV diagnostics market in 2024, based on end user."
The HIV diagnostics market is segmented by end users into diagnostic laboratories, hospitals, blood banks, home care settings, and others. In 2024, diagnostic laboratories accounted for the largest market share, driven by the increasing prevalence of HIV/AIDS, the expansion of diagnostic facilities, the rising demand for sample testing, and advancements in point-of-care (POC) technology.
The HIV diagnostics market is segmented into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2024, North America led the global market, driven by factors such as the rising prevalence of HIV/AIDS, advancements in point-of-care (POC) diagnostic instruments and test kits, growing awareness initiatives, and an increase in blood transfusions and donations. The presence of well-established healthcare infrastructure, significant investments in research and development, and supportive government policies further contributed to the region's market dominance.
However, the Asia Pacific region is projected to experience the highest compound annual growth rate during the forecast period. This rapid expansion is fueled by the rising number of HIV cases, the increasing availability of advanced POC diagnostic products, and growing healthcare investments in emerging economies. Additionally, government-led initiatives promoting HIV awareness, improved healthcare accessibility, and a surge in global market players expanding their presence in the region are further accelerating market growth. The region's increasing focus on early disease detection, combined with technological advancements and growing collaborations between public and private healthcare organizations, is expected to create significant opportunities for market expansion.
The break-up of the profile of primary participants in the HIV diagnostics market:
By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
By Designation: M-level - 30%, D-level - 50%, and Others - 20%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Others-4%
The key players in this market are are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMerieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others.
Research Coverage:
This research report categorizes the HIV diagnostics market by device type (consumables, instruments, software & services ), by test type (screening tests, confirmatory tests, monitoring tests and other HIV diagnostic tests), by end user (diagnostic laboratories, blood banks, home care settings, hospitals and other endusers), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the HIV diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the HIV diagnostics market. Competitive analysis of upcoming startups in the HIV diagnostics market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HIV diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Rising prevalence of HIV/AIDS, Increasing number of blood transfusions & blood donations, Advantages offered by POC diagnostic kits & instruments) opportunities (Growth opportunities in emerging economies), restraints (high cost of NATs), and challenges (lack of skilled workforce) influencing the growth of the HIV diagnostics market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the HIV diagnostics market.
Market Development: Comprehensive information about lucrative markets - the report analyses the HIV diagnostics market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HIV diagnostics market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain).
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
2.4 MARKET SHARE ASSUMPTIONS
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 HIV DIAGNOSTICS MARKET OVERVIEW
4.2 GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of HIV/AIDS
5.2.1.2 Increasing number of blood transfusions & blood donations
5.2.1.3 Advantages offered by POC diagnostic kits & instruments
5.2.1.4 Increasing initiatives for HIV awareness campaigns
5.2.2 RESTRAINTS
5.2.2.1 High cost of NATs
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
5.2.3.2 Trend of self-testing and growing preference for at- home diagnostic kits
5.2.4 CHALLENGES
5.2.4.1 Operational barriers and shortage of skilled laboratory technicians
